Wanbangde Pharmaceutical Holding Group Co Ltd - Asset Resilience Ratio

Latest as of June 2025: 0.24%

Wanbangde Pharmaceutical Holding Group Co Ltd (002082) has an Asset Resilience Ratio of 0.24% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 002082 working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥10.41 Million
≈ $1.52 Million USD Cash + Short-term Investments

Total Assets

CN¥4.43 Billion
≈ $647.96 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2004–2024)

This chart shows how Wanbangde Pharmaceutical Holding Group Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Wanbangde Pharmaceutical Holding Group C asset portfolio.

Liquid Assets Composition Over Time

This chart breaks down Wanbangde Pharmaceutical Holding Group Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read 002082 liabilities breakdown for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥10.41 Million 0.24%
Total Liquid Assets CN¥10.41 Million 0.24%

Asset Resilience Insights

  • Limited Liquidity: Wanbangde Pharmaceutical Holding Group Co Ltd maintains only 0.24% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Wanbangde Pharmaceutical Holding Group Co Ltd Industry Peers by Asset Resilience Ratio

Compare Wanbangde Pharmaceutical Holding Group Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
Drug Manufacturers - Specialty & Generic 1.54%
Yunnan Baiyao Group Co Ltd
SHE:000538
Drug Manufacturers - Specialty & Generic 8.38%
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
Drug Manufacturers - Specialty & Generic 6.62%
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
Drug Manufacturers - Specialty & Generic 4.94%
Harbin Gloria Pharmaceuticals
SHE:002437
Drug Manufacturers - Specialty & Generic 9.04%
Jiuzhitang Co Ltd
SHE:000989
Drug Manufacturers - Specialty & Generic 7.86%
Renhe Pharmacy Co Ltd
SHE:000650
Drug Manufacturers - Specialty & Generic 37.54%
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
Drug Manufacturers - Specialty & Generic 0.29%

Annual Asset Resilience Ratio for Wanbangde Pharmaceutical Holding Group Co Ltd (2004–2024)

The table below shows the annual Asset Resilience Ratio data for Wanbangde Pharmaceutical Holding Group Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 0.26% CN¥11.15 Million
≈ $1.63 Million
CN¥4.33 Billion
≈ $633.23 Million
-1.74pp
2014-12-31 2.00% CN¥31.00 Million
≈ $4.54 Million
CN¥1.55 Billion
≈ $226.96 Million
+1.92pp
2005-12-31 0.07% CN¥491.18K
≈ $71.88K
CN¥661.73 Million
≈ $96.83 Million
-0.05pp
2004-12-31 0.12% CN¥517.57K
≈ $75.74K
CN¥416.66 Million
≈ $60.97 Million
--
pp = percentage points

About Wanbangde Pharmaceutical Holding Group Co Ltd

SHE:002082 China Drug Manufacturers - Specialty & Generic
Market Cap
$856.60 Million
CN¥5.85 Billion CNY
Market Cap Rank
#9650 Global
#2486 in China
Share Price
CN¥9.57
Change (1 day)
+0.00%
52-Week Range
CN¥8.94 - CN¥36.24
All Time High
CN¥36.24
About

Wanbangde Pharmaceutical Holding Group Co., Ltd. engages in the research and development, production, and sale of traditional Chinese medicine, chemical raw materials, and chemical preparations in China and internationally. The company operates through two segments, the Pharmaceutical Business and the Medical Device Business. It offers drugs products used to treat cardiovascular and cerebrovascul… Read more